Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death

Cancer Discovery

Volumn 3, Issue 10, 2013, Pages 1130-1141

  Heaphy, Christopher M ^a   Yoon, Ghil Suk ^a,f   Peskoe, Sarah B ^b   Joshu, Corinne E ^b   Lee, Thomas K ^a   Giovannucci, Edward ^d,e   Mucci, Lorelei A ^d,e   Kenfield, Stacey A ^d,e   Stampfer, Meir J ^d,e   Hicks, Jessica L ^a   De Marzo, Angelo M ^a,c   Platz, Elizabeth A ^a,b,c   Meeker, Alan K ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Kyungpook National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BIOPSY; CANCER GROWTH; CANCER MORTALITY; CELL DEATH; CELL DIVISION; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GLEASON SCORE; HEALTH PRACTITIONER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STROMA CELL; METASTASIS; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; TELOMERE HOMEOSTASIS; TELOMERE LENGTH;

AGED; CHROMOSOMAL INSTABILITY; COHORT STUDIES; DISEASE-FREE SURVIVAL; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; STROMAL CELLS; TELOMERE;

EID: 84884703040     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0135     Document Type: Article

References (28)

1. Blackburn EH. Telomeres. Trends Biochem Sci 1991; 16: 378-81.
2. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet 2008; 42: 301-34.
3. O'Sullivan RJ, Karlseder J. Telomeres: protecting chromosomes against genome instability. Nat Rev Mol Cell Biol 2010; 11: 171-81.
4. Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ, et al. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res 2002; 62: 6405-9.
5. Fordyce CA, Heaphy CM, Joste NE, Smith AY, Hunt WC, Griffith JK. Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol 2005; 173: 610-4.
6. Treat EG, Heaphy CM, Massie LW, Bisoffi M, Smith AY, Davis MS, et al. Telomere DNA content in prostate biopsies predicts early rise in prostate-specific antigen after radical prostatectomy for prostate cancer. Urology 2010; 75: 724-9.
7. Donaldson L, Fordyce C, Gilliland F, Smith A, Feddersen R, Joste N, et al. Association between outcome and telomere DNA content in prostate cancer. J Urol 1999; 162: 1788-92.
8. Merlo LM, Maley CC. The role of genetic diversity in cancer. J Clin Invest 2010; 120: 401-3.
9. Meeker AK, Gage WR, Hicks JL, Simon I, Coffman JR, Platz EA, et al. Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol 2002; 160: 1259-68.
10. de Lange T. How telomeres solve the end-protection problem. Science 2009; 326: 948-52.
11. Vaziri H. Critical telomere shortening regulated by the ataxia-telangiectasia gene acts as a DNA damage signal leading to activation of p53 protein and limited life-span of human diploid fibroblasts. A review. Biochemistry 1997; 62: 1306-10.
12. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426: 194-8.
13. Maser RS, DePinho RA. Connecting chromosomes, crisis, and cancer. Science 2002; 297: 565-9.
14. Vukovic B, Park PC, Al-Maghrabi J, Beheshti B, Sweet J, Evans A, et al. Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene 2003; 22: 1978-87.
15. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406: 641-5.
16. Heaphy CM, Fleet TM, Treat EG, Lee SJ, Smith AY, Davis MS, et al. Organ-wide telomeric status in diseased and disease-free prostatic tissues. Prostate 2010; 70: 1471-9.
17. Joshua AM, Shen E, Yoshimoto M, Marrano P, Zielenska M, Evans AJ, et al. Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies. Prostate 2011; 71: 778-90.
18. Richardson AM, Woodson K, Wang Y, Rodriguez-Canales J, Erickson HS, Tangrea MA, et al. Global expression analysis of prostate cancer-associated stroma and epithelia. Diagn Mol Pathol 2007; 16: 189-97.
19. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002; 160: 2169-80.
20. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 2003; 9: 4792-801.
21. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, et al. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 2004; 92: 221-36.
22. Sung SY, Chung LW. Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation 2002; 70: 506-21.
23. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010; 5: 99-118.
24. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012; 12: 323-34.
25. Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, et al. Test of the national death index. Am J Epidemiol 1984; 119: 837-9.
26. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009; 27: 3459-64.
27. Dhillon PK, Barry M, Stampfer MJ, Perner S, Fiorentino M, Fornari A, et al. Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2009; 18: 595-600.
28. Kremers W. Concordance for survival time data including timedependent covariates accounting for ties in predictor and time. Technical report. Rochester (MN): The William J. von Liebig Transplant Center; 2007 April. Report no. 80.